Masatake Kobayashi1,2, Patrick Rossignol1,3, João Pedro Ferreira1,4, Irene Aragão4, Yuki Paku2, Yoichi Iwasaki2, Masataka Watanabe2, Marat Fudim5,6, Kevin Duarte1, Faiez Zannad1,3, Nicolas Girerd7,8. 1. INSERM, Centre d'Investigations Cliniques 1433, Centre d'Investigation Clinique Pierre Drouin, CHRU de Nancy, Inserm 1116 and INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network, Institut lorrain du coeur et des, vaisseaux Louis Mathieu, Université de Lorraine, 4, rue du Morvan, 54500, Nancy, Vandoeuvre-Les-Nancy, France. 2. Department of Cardiology, Tokyo Medical University, Tokyo, Japan. 3. Département de Cardiologie, CHRU de Nancy, Nancy, France. 4. Cardiovascular Research and Development Unit, Department of Physiology and Cardiothoracic Surgery, Faculty of Medicine, University of Porto, Porto, Portugal. 5. Duke University Medical Center, Durham, NC, USA. 6. Duke Clinical Research Institute, Durham, NC, USA. 7. INSERM, Centre d'Investigations Cliniques 1433, Centre d'Investigation Clinique Pierre Drouin, CHRU de Nancy, Inserm 1116 and INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network, Institut lorrain du coeur et des, vaisseaux Louis Mathieu, Université de Lorraine, 4, rue du Morvan, 54500, Nancy, Vandoeuvre-Les-Nancy, France. n.girerd@chru-nancy.fr. 8. Département de Cardiologie, CHRU de Nancy, Nancy, France. n.girerd@chru-nancy.fr.
Abstract
AIMS: Estimated plasma volume status (ePVS) predicts prognosis in patients with heart failure (HF). It remains unclear whether admission, discharge or change ePVS best predicts post-discharge outcome in patients with acute decompensated heart failure (ADHF). METHODS: We retrospectively analyzed three cohort studies: 383 patients admitted at the Tokyo Medical University hospital, 165 patients admitted at the Centro Hospitalar do Porto and 164 patients admitted at the Nancy University Hospital (ICALOR study). ePVS at admission and at discharge as well as its change thereof were, respectively, calculated using the Duarte and Strauss formulas, both derived from hemoglobin and hematocrit ratios. Clinical variables including physical assessment, biological and echocardiographic parameters were recorded. The clinical outcome was a composite of re-hospitalization for worsening HF or all-cause mortality [corrected]. RESULTS: The primary outcomes occurred in 27.2% at 1 year (in the Tokyo cohort), 45.3% at 6 months (in the Porto cohort) and 53.9% at median terms of 298.3 days (in the ICALOR study). After adjusting for potential confounders including natriuretic peptide, discharge ePVS remained significantly associated with increased rates of composite outcome in the Tokyo and Porto cohorts and ICALOR study [hazard ratio (HR) 1.21 (1.01-1.44), p = 0.04; HR 1.45 (1.16-1.81), p < 0.01; HR 1.45 (1.16-1.81), p < 0.01, respectively]. In addition, a pooled analysis yielded a significant improvement in reclassification with discharge ePVS [net reclassification index 13.6% (5.9-22.7), p = 0.004]. CONCLUSIONS: As validated in three independent ADHF cohorts, ePVS at discharge was independently associated with post-discharge clinical outcomes and improved the risk stratification of patients admitted for ADHF on top of well-established prognostic markers.
AIMS: Estimated plasma volume status (ePVS) predicts prognosis in patients with heart failure (HF). It remains unclear whether admission, discharge or change ePVS best predicts post-discharge outcome in patients with acute decompensated heart failure (ADHF). METHODS: We retrospectively analyzed three cohort studies: 383 patients admitted at the Tokyo Medical University hospital, 165 patients admitted at the Centro Hospitalar do Porto and 164 patients admitted at the Nancy University Hospital (ICALOR study). ePVS at admission and at discharge as well as its change thereof were, respectively, calculated using the Duarte and Strauss formulas, both derived from hemoglobin and hematocrit ratios. Clinical variables including physical assessment, biological and echocardiographic parameters were recorded. The clinical outcome was a composite of re-hospitalization for worsening HF or all-cause mortality [corrected]. RESULTS: The primary outcomes occurred in 27.2% at 1 year (in the Tokyo cohort), 45.3% at 6 months (in the Porto cohort) and 53.9% at median terms of 298.3 days (in the ICALOR study). After adjusting for potential confounders including natriuretic peptide, discharge ePVS remained significantly associated with increased rates of composite outcome in the Tokyo and Porto cohorts and ICALOR study [hazard ratio (HR) 1.21 (1.01-1.44), p = 0.04; HR 1.45 (1.16-1.81), p < 0.01; HR 1.45 (1.16-1.81), p < 0.01, respectively]. In addition, a pooled analysis yielded a significant improvement in reclassification with discharge ePVS [net reclassification index 13.6% (5.9-22.7), p = 0.004]. CONCLUSIONS: As validated in three independent ADHF cohorts, ePVS at discharge was independently associated with post-discharge clinical outcomes and improved the risk stratification of patients admitted for ADHF on top of well-established prognostic markers.
Authors: Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer Journal: Eur J Heart Fail Date: 2016-05-20 Impact factor: 15.534
Authors: Mihai Gheorghiade; Ferenc Follath; Piotr Ponikowski; Jeffrey H Barsuk; John E A Blair; John G Cleland; Kenneth Dickstein; Mark H Drazner; Gregg C Fonarow; Tiny Jaarsma; Guillaume Jondeau; Jose Lopez Sendon; Alexander Mebazaa; Marco Metra; Markku Nieminen; Peter S Pang; Petar Seferovic; Lynne W Stevenson; Dirk J van Veldhuisen; Faiez Zannad; Stefan D Anker; Andrew Rhodes; John J V McMurray; Gerasimos Filippatos Journal: Eur J Heart Fail Date: 2010-03-30 Impact factor: 15.534
Authors: Andrew P Ambrosy; Peter S Pang; Sadiya Khan; Marvin A Konstam; Gregg C Fonarow; Brian Traver; Aldo P Maggioni; Thomas Cook; Karl Swedberg; John C Burnett; Liliana Grinfeld; James E Udelson; Faiez Zannad; Mihai Gheorghiade Journal: Eur Heart J Date: 2013-01-04 Impact factor: 29.983
Authors: Andrew P Ambrosy; Ankeet S Bhatt; Dianne Gallup; Kevin J Anstrom; Javed Butler; Adam D DeVore; G Michael Felker; Marat Fudim; Stephen J Greene; Adrian F Hernandez; Jacob P Kelly; Marc D Samsky; Robert J Mentz Journal: Am J Cardiol Date: 2017-04-12 Impact factor: 2.778
Authors: Peter van der Meer; Douwe Postmus; Piotr Ponikowski; John G Cleland; Christopher M O'Connor; Gad Cotter; Marco Metra; Beth A Davison; Michael M Givertz; George A Mansoor; John R Teerlink; Barry M Massie; Hans L Hillege; Adriaan A Voors Journal: J Am Coll Cardiol Date: 2013-03-14 Impact factor: 24.094
Authors: Paul R Kalra; Constantinos Anagnostopoulos; Aidan P Bolger; Andrew J S Coats; Stefan D Anker Journal: J Am Coll Cardiol Date: 2002-06-19 Impact factor: 24.094
Authors: Stephen J Greene; Mihai Gheorghiade; Muthiah Vaduganathan; Andrew P Ambrosy; Robert J Mentz; Haris Subacius; Aldo P Maggioni; Savina Nodari; Marvin A Konstam; Javed Butler; Gerasimos Filippatos Journal: Eur J Heart Fail Date: 2013-07-11 Impact factor: 15.534
Authors: Maria Rosa Costanzo; Claudio Ronco; William T Abraham; Piergiuseppe Agostoni; Jonathan Barasch; Gregg C Fonarow; Stephen S Gottlieb; Brian E Jaski; Amir Kazory; Allison P Levin; Howard R Levin; Giancarlo Marenzi; Wilfried Mullens; Dan Negoianu; Margaret M Redfield; W H Wilson Tang; Jeffrey M Testani; Adriaan A Voors Journal: J Am Coll Cardiol Date: 2017-05-16 Impact factor: 24.094
Authors: Justas Simonavičius; Micha T Maeder; Casper G M J Eurlings; Arantxa Barandiarán Aizpurua; Jelena Čelutkienė; Jūratė Barysienė; Stefan Toggweiler; Beat A Kaufmann; Hans-Peter Brunner-La Rocca Journal: Clin Res Cardiol Date: 2020-11-20 Impact factor: 5.460
Authors: Masatake Kobayashi; Luna Gargani; Alberto Palazzuoli; Giuseppe Ambrosio; Antoni Bayés-Genis; Josep Lupon; Pierpaolo Pellicori; Nicola Riccardo Pugliese; Yogesh N V Reddy; Gaetano Ruocco; Kevin Duarte; Olivier Huttin; Patrick Rossignol; Stefano Coiro; Nicolas Girerd Journal: Clin Res Cardiol Date: 2020-08-08 Impact factor: 5.460